Company: Dr. Reddy's Laboratories Ltd. Category: Result Analysis


Dr. Reddys Lab’s (DRL) revenue, increased by 13.6% YoY to Rs40.2 bn, is higher than our estimates of Rs 38.9bn; primarily due to good growth in Europe and Emerging market business. EBITDA margins grew to21.2% inline with our estimates of 21.0% on account of lower SGA and R & D expenses.
May 20, 2019, 1 p.m.

NULL
May 17, 2019, 3:50 p.m.
Publisher: moneycontrol.com

NULL
May 17, 2019, 3:50 p.m.
Publisher: moneycontrol.com

Dr. Reddy’s Laboratories or DRL’s revenues in 3QFY19 at Rs 38,500mn were in line with our estimate as well as consensus estimate. However, net earnings at Rs4,878mn were 10%/29% above our estimate/consensus estimate, respectively.
Feb. 4, 2019, 11:34 a.m.
Publisher: nirmalbang.com


NULL
Feb. 1, 2019, 6:38 p.m.
Publisher: moneycontrol.com

Revenues from the quarter under review was up by one percent to Rs 3,850 crore, accordig to a press release by the city-based pharma major. It was Rs 3,806 crore in the same quarter last fiscal.
Feb. 1, 2019, 3:53 p.m.
Publisher: moneycontrol.com

DRL’s revenues increased by 7% YoY to Rs 37.9 bn (lower than our estimates of Rs 38.9 bn) primarily due to de-growth in US business on account of higher pricing pressure due to incremental competition in some of the key products.
Oct. 29, 2018, 11:38 a.m.

Dr. Reddy’s Laboratories or DRL’s 2QFY19 earnings at Rs5,038mn were 35%/45% above our/consensus estimates, respectively, and up 10.5% QoQ.
Oct. 29, 2018, 11:29 a.m.
Publisher: nirmalbang.com

NULL
Oct. 26, 2018, 3:37 p.m.
Publisher: moneycontrol.com

DRRD’s sales are in line with our estimates while EBITDA missed by 8% due to higher contribution of low margin sales from emerging markets.
Oct. 26, 2018, 11:47 a.m.
Publisher: plindia.com

-->